Performance of the Rapid High-throughput Automated Electrochemiluminescence Immunoassay Targeting Total Antibodies to the SARS-CoV-2 Spike Protein Receptor Binding Domain in Comparison to the Neutralization Assay

Overview

Journal J Clin Virol

Specialty Microbiology

Date 2021 Apr 17

PMID 33865031

Citations 67

Authors

Katarina Resman Rus

Misa Korva

Natasa Knap

Tatjana Avsic Zupanc

Mario Poljak

Affiliations

Soon will be listed here.

Abstract

Background: Neutralization tests (NT) are the gold standard for detecting and quantifying anti-SARS-CoV-2 neutralizing antibodies (NAb), but their complexity restricts them to research settings or reference laboratories. Antibodies against S protein receptor binding domain (RBD) have been shown to confer a neutralizing activity against SARS-CoV-2. Assays quantitatively measuring anti-S1-RBD-SARS-CoV-2 antibodies could be of great value for NAb screening of potential donors for convalescent-phase plasma therapy, assessing natural or vaccine-induced immunity, stratifying individuals for vaccine receipt, and documenting vaccine response.

Methods: Elecsys Anti-SARS-CoV-2 S (Elecsys-S), a high-throughput automated electrochemiluminescence double-antigen sandwich immunoassay for quantitative measurement of pan-anti-S1-RBD-SARS-CoV-2 antibodies, was evaluated against NT on 357 patients with PCR-confirmed SARS-CoV-2 infection. NT was performed in a BSL-3 laboratory using a Slovenian SARS-CoV-2 isolate; the NT titer ≥1:20 was considered positive.

Results: Elecsys-S detected pan-anti-S1-RBD-SARS-CoV-2 antibodies in 352/357 (98.6 %) samples. NAb were identified by NT in 257/357 (72 %) samples. The Elecsys-S/NT agreement was moderate (Cohen's kappa 0.56). High NT titer antibodies (≥1:160) were detected in 106/357 (30 %) samples. Elecsys-S's pan-anti-S1-RBD-SARS-CoV-2 antibody concentrations correlated with individual NT titer categories (the lowest concentrations were identified in NT-negative samples and the highest in samples with NT titer 1:1,280), and the Elecsys-S cutoff value for reasonable prediction of NAb generated after natural infection was established (133 BAU/mL).

Conclusion: Although NT should remain the gold standard for assessing candidates for convalescent-phase plasma donors, selected commercial anti-SARS-CoV-2 assays with optimized cutoff, like Elecsys-S, could be used for rapid, automated, and large-scale screening of individuals with clinically relevant NAb levels as suitable donors.

Citing Articles

Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.

Ben Jemaa A, Bouabsa R, Ben Othmen M, Oueslati R, Dhaouadi H Tunis Med. 2024; 102(8):457-464.

PMID: 39129572 PMC: 11390062. DOI: 10.62438/tunismed.v102i8.4944.

Overcoming the age-dependent SARS-CoV-2 vaccine response through hybrid immunity: analysis of humoral and cellular immunity with mass cytometry profiling.

Gerelkhuu Z, Park S, Lee K, Kim Y, Kwon S, Song K Immun Ageing. 2024; 21(1):51.

PMID: 39080742 PMC: 11289962. DOI: 10.1186/s12979-024-00454-z.

Serological response after COVID-19 infection compared to vaccination against COVID-19 in children with autoimmune rheumatic diseases.

Sinkovec Savsek T, Zajc Avramovic M, Avcin T, Korva M, Avsic-Zupanc T, Toplak N Pediatr Rheumatol Online J. 2024; 22(1):68.

PMID: 39054538 PMC: 11271209. DOI: 10.1186/s12969-024-01003-0.

Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon.

Nour D, Ismail M, Osman M, Rafei R, Kasir D, Dabboussi F PLoS One. 2024; 19(5):e0302579.

PMID: 38722969 PMC: 11081361. DOI: 10.1371/journal.pone.0302579.

Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients.

Lerdsamran H, Anusorntanawat R, Sangsiriwut K, Sawadpongpan S, Prasertsopon J, Thinpan N PLoS One. 2024; 19(4):e0298033.

PMID: 38626137 PMC: 11020499. DOI: 10.1371/journal.pone.0298033.

References

Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M . Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2. J Clin Microbiol. 2020; 58(10). PMC: 7512151. DOI: 10.1128/JCM.01694-20. View

Turbett S, Anahtar M, Dighe A, Garcia Beltran W, Miller T, Scott H . Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms. J Clin Microbiol. 2020; 59(1). PMC: 7771444. DOI: 10.1128/JCM.01892-20. View

Hanson K, Caliendo A, Arias C, Englund J, Hayden M, Lee M . Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing. Clin Infect Dis. 2020; . PMC: 7543294. DOI: 10.1093/cid/ciaa1343. View

Schaffner A, Risch L, Aeschbacher S, Risch C, Weber M, Thiel S . Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J Clin Med. 2020; 9(12). PMC: 7764650. DOI: 10.3390/jcm9123989. View

Theel E, Couturier M, Filkins L, Palavecino E, Mitchell S, Campbell S . Application, Verification, and Implementation of SARS-CoV-2 Serologic Assays with Emergency Use Authorization. J Clin Microbiol. 2020; 59(1). PMC: 7771455. DOI: 10.1128/JCM.02148-20. View

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X . Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020; 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z. View

Watson J, Richter A, Deeks J . Testing for SARS-CoV-2 antibodies. BMJ. 2020; 370:m3325. DOI: 10.1136/bmj.m3325. View

Harley K, Gunsolus I . Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays. J Clin Microbiol. 2020; 59(1). PMC: 7771433. DOI: 10.1128/JCM.02104-20. View

Bastos M, Tavaziva G, Abidi S, Campbell J, Haraoui L, Johnston J . Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020; 370:m2516. PMC: 7327913. DOI: 10.1136/bmj.m2516. View

10.

Poljak M, Korva M, Knap Gasper N, Fujs Komlos K, Sagadin M, Ursic T . Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic. J Clin Microbiol. 2020; 58(6). PMC: 7269406. DOI: 10.1128/JCM.00599-20. View

11.

Rijkers G, Murk J, Wintermans B, van Looy B, van den Berge M, Veenemans J . Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. J Infect Dis. 2020; 222(8):1265-1269. PMC: 7454692. DOI: 10.1093/infdis/jiaa463. View

12.

Bal A, Trabaud M, Fassier J, Rabilloud M, Saker K, Langlois-Jacques C . Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays. Clin Microbiol Infect. 2021; 27(6):933-935. PMC: 7803622. DOI: 10.1016/j.cmi.2021.01.003. View

13.

Mekonnen D, Mengist H, Derbie A, Nibret E, Munshea A, He H . Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta-analysis. Rev Med Virol. 2020; 31(3):e2181. DOI: 10.1002/rmv.2181. View

14.

Hicks S, Pohl K, Neeman T, McNamara H, Parsons K, He J . A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. J Infect Dis. 2020; 223(1):10-14. PMC: 7665523. DOI: 10.1093/infdis/jiaa623. View

15.

Zilla M, Wheeler B, Keetch C, Mitchell G, McBreen J, Wells A . Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening. Am J Clin Pathol. 2020; 155(3):343-353. PMC: 7665309. DOI: 10.1093/ajcp/aqaa228. View

16.

Joyner M, Carter R, Senefeld J, Klassen S, Mills J, Johnson P . Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021; 384(11):1015-1027. PMC: 7821984. DOI: 10.1056/NEJMoa2031893. View

17.

Lee W, Girardin R, Dupuis A, Kulas K, Payne A, Wong S . Neutralizing Antibody Responses in COVID-19 Convalescent Sera. J Infect Dis. 2020; 223(1):47-55. PMC: 7665673. DOI: 10.1093/infdis/jiaa673. View

18.

Manthei D, Whalen J, Schroeder L, Sinay A, Li S, Valdez R . Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples. Am J Clin Pathol. 2020; 155(2):267-279. PMC: 7665294. DOI: 10.1093/ajcp/aqaa200. View

19.

Armstrong R . When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014; 34(5):502-8. DOI: 10.1111/opo.12131. View